Current Use and Trends in Hematopoietic Cell Transplantation in the United States

Biology of Blood and Marrow Transplantation

Volumn 23, Issue 9, 2017, Pages 1417-1421

  D'Souza, Anita ^a,b   Lee, Stephanie ^a,c   Zhu, Xiaochun ^a   Pasquini, Marcelo ^a,b  

^a CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

HCT activity; Trends; US

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; HLA ANTIGEN; METHOTREXATE; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; MYELOABLATIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADULT; AGE; APLASTIC ANEMIA; BONE MARROW; CAUSE OF DEATH; CLINICAL OUTCOME; EDITORIAL; ETHNICITY; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY RATE; MULTIPLE MYELOMA; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROPHYLAXIS; RACE; RECIPIENT; REDUCED INTENSITY CONDITIONING; SOLID MALIGNANT NEOPLASM; SURVIVAL RATE; T CELL DEPLETION; TREATMENT INDICATION; TREND STUDY; UMBILICAL CORD BLOOD; UNITED STATES; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHILD; CLASSIFICATION; CYTOLOGY; DONOR; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MORTALITY; PATHOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRENDS;

ADULT; ALEMTUZUMAB; ANTILYMPHOCYTE SERUM; CALCINEURIN INHIBITORS; CHILD; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HISTOCOMPATIBILITY TESTING; HUMANS; METHOTREXATE; MYELOABLATIVE AGONISTS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85023159496     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2017.05.035     Document Type: Editorial

References (5)

1. Gratwohl, A., Pasquini, M.C., Aljurf, M.D., et al. Global hematopoietic stem cell transplantation (HSCT) at one million: an achievement of pioneers and foreseeable challenges for the next decade. A report from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Blood, 122, 2013, 2133.
2. D'Souza, A., Zhu, X., Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides. Available at: http://www.cibmtr.org, 2016 Accessed March 2017.
3. Bacigalupo, A., Ballen, K., Rizzo, D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15 (2009), 1628–1633.
4. Giralt, S., Ballen, K., Rizzo, D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 15 (2009), 367–369.
5. Atallah, E., Horowitz, M.M., Logan, B., et al. Outcome of patients 65 years and older with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age. Blood, 126, 2015, 193.